Repurposing a Histone Deacetylase 2 (HDAC-2) Specific Inhibitor as a Potential Treatment for Alzheimer's Disease (AD)

被引：0
|
作者：
Ibia, I. E. [1 ]
Mobbs, C. V. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Reston, VA USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
B127
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [21] Effect of histone deacetylase (HDAC) inhibitor on gene expression in MDM2 transfected prostate cancer cells
    Venkatesan, Thiagarajan
    Alaseem, Ali
    Alhazzani, Khalid
    Kanagasabai, Thanigaivelan
    Rathinavelu, Appu
    CANCER RESEARCH, 2017, 77
  • [22] Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat
    Carmine Carbone
    Elena Di Gennaro
    Geny Piro
    Maria Rita Milone
    Biagio Pucci
    Michele Caraglia
    Alfredo Budillon
    Amino Acids, 2017, 49 : 517 - 528
  • [23] Development of a Neutral Sphingomyelinase 2 Inhibitor for the Treatment of Alzheimer's Disease
    Hollinger, Kristen R.
    Bell, Benjamin J.
    Sala, Michal
    Dash, Ranjeet P.
    Thomas, Ajit G.
    Chaudhuri, Amrita Datta
    Kumar, Asit
    Lovell, Lyndah
    Wu, Ying
    Rais, Rana
    Haughey, Norman
    Nencka, Radim
    Rojas, Camilo
    Slusher, Barbara S.
    NEUROTHERAPEUTICS, 2020, 17 (03) : 1313 - 1314
  • [24] Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020)
    Li, Yunheng
    Sang, Shenghu
    Ren, Weijie
    Pei, Yuqiong
    Bian, Yaoyao
    Chen, Yao
    Sun, Haopeng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 226
  • [25] Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment
    Barnes, PJ
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (06) : 1111 - 1121
  • [26] Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
    Niesvizky, Ruben
    Ely, Scott
    Mark, Tomer
    Aggarwal, Sangeeta
    Gabrilove, Janice L.
    Wright, John J.
    Chen-Kiang, Selina
    Sparano, Joseph A.
    CANCER, 2011, 117 (02) : 336 - 342
  • [27] An orally bioavailable and selective histone deacetylase (HDAC) 1 & 2 inhibitor enhances retinoic acid mediated differentiation of neuroblastoma
    Tamang, David L.
    Huang, Pengyu
    Golonzhka, Olga
    Shearstone, Jeffrey R.
    Quayle, Steven N.
    Jones, Simon S.
    Yang, Min
    CANCER RESEARCH, 2016, 76
  • [28] LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease
    Bhattarai, Deepak
    Lee, Min Jae
    Baek, Ahruem
    Yeo, In Jun
    Miller, Zachary
    Baek, Yu Mi
    Lee, Sukyeong
    Kim, Dong-Eun
    Hong, Jin Tae
    Kim, Kyung Bo
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (07) : 3763 - 3783
  • [29] Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Ohyashiki, Kazuma
    BLOOD, 2011, 118 (21) : 612 - 612
  • [30] L1CAM Beneficially Inhibits Histone Deacetylase 2 Expression under Conditions of Alzheimer's Disease
    Hu, Chengliang
    Hu, Junkai
    Meng, Xianghe
    Zhang, Hongli
    Shen, Huifan
    Huang, Peizhi
    Schachner, Melitta
    Zhao, Weijiang
    CURRENT ALZHEIMER RESEARCH, 2020, 17 (04) : 382 - 392
12345